APOE and Alzheimer disease: Studies utilising fluorodeoxyglucose positron emission tomography have revealed a decrease in glucose uptake prior to the onset of disease symptoms in individuals at risk of developing AD, including those with familial AD (fAD) and apolipoprotein E (ApoE) 4 carriers.